Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Oreola Donini, PhD, Chief Scientific Officer, will be presenting key data from the Company's thermostable vaccine technology platform, including results from the Company's programs for ricin toxin vaccine (RiVax®), COVID-19 vaccine (CiVax™) and filovirus vaccines (targeting Ebola, Sudan, and Marburg viruses). The presentation will be given at the upcoming 6th International Conference on Vaccines Research and Development, Online, on November 1-3, 2021.
A Thermal Stabilization Platform for Subunit Proteins Compatible with Multiple Adjuvants, with Data from Ricin Toxin, Filovirus and COVID-19 Vaccine Candidates presented by Oreola Donini, PhD, Chief Scientific Officer, on November 2, 2021 from 9:30 – 10:00 AM EST. The official program is here.
Under the Company's Public Health Solutions business segment, Soligenix is developing thermostabilized subunit vaccines. Thermostabilization is achieved by using a combination of Generally Recognized as Safe (GRAS) excipients and lyophilization (freeze-drying) to yield a single-vial presentation of vaccine that is stable at ambient and higher temperatures and that can be reconstituted with water for injection immediately prior to use. The most advanced program is RiVax®, a ricin toxin vaccine utilizing an alum adjuvant. The thermostabilized RiVax® product has been demonstrated to achieve up to 100% protection, even after lethal aerosol exposure to ricin in non-human primates, and to be fully potent even after at least 12 months storage at 40 degrees Celsius (104 degrees Fahrenheit).
The filovirus and CiVax™ programs use similar formulation conditions in combination with a novel nano-emulsion adjuvant, CoVaccine HT™. Ongoing collaborations have demonstrated the feasibility of developing thermally-stable single-vial presentation vaccines for all three filoviruses, as well as combination vaccines in a single-vial formulation (mono-, bi- and tri-valent vaccines) that has the potential to enable generation of broader protective vaccines. Most recently, the antigen and adjuvant manufacturing advances demonstrated in the filovirus program have been found to be similarly effective in the CiVax™ program. This simple delivery format, as well as the compatibility with ambient storage, enables vaccines that significantly reduce the logistical hurdles that have been required for addressing both filovirus and COVID-19 pandemics. The filovirus and CiVax™ vaccine programs are continuing to advance with the support of a National Institute of Health (NIH) grant R01-AI132323 (awarded to the University of Hawaii) and a Small Business Innovation Research grant (#1R44AI157593-01; awarded to Soligenix, Inc.).
About the 6th International Conference on Vaccines Research a